A Dark Vector Cognition product

Cover and table of contents

19K characters. Original on sec.gov ·

Cover and table of contents

The 9 tables in Cover and table of contents as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-37702

Amgen Inc.

(Exact name of registrant as specified in its charter)

Delaware95-3540776
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
One Amgen Center Drive91320-1799
Thousand Oaks
California
(Address of principal executive offices)(Zip Code)

(805) 447-1000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.0001 par valueAMGNThe Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☑Accelerated filer☐Non-accelerated filer☐
Smaller reporting company☐Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☑

As of October 29, 2026, the registrant had 540,911,490 shares of common stock, $0.0001 par value, outstanding.

AMGEN INC.

INDEX

Page No.
DEFINED TERMS AND PRODUCTSii
PART I—FINANCIAL INFORMATION1
Item 1.FINANCIAL STATEMENTS1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME2
CONDENSED CONSOLIDATED BALANCE SHEETS3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS6
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS7
Item 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS31
Item 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK46
Item 4.CONTROLS AND PROCEDURES47
PART II—OTHER INFORMATION48
Item 1.LEGAL PROCEEDINGS48
Item 1A.RISK FACTORS48
Item 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS56
Item 5.OTHER INFORMATION56
Item 6.EXHIBITS56
INDEX TO EXHIBITS57
SIGNATURES63

i

Defined Terms and Products

Defined terms

We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as well as names of other companies, which are provided below.

TermDescription
2017 Tax ActTax Cuts and Jobs Act of 2017
340B ProgramFederal 340B Drug Pricing Program
AAVanti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
AOCIaccumulated other comprehensive income (loss)
AstraZenecaAstraZeneca plc
BeOneBeOne Medicines Ltd. (formerly BeiGene, Ltd.)
CDERFDA’s Center for Drug Evaluation and Research
ChemoCentryxChemoCentryx, Inc.
CMSCenters for Medicare & Medicaid Services
DILIdrug-induced liver injury
DSCDrug Safety Communication
EMAEuropean Medicines Agency
EPSearnings per share
EUEuropean Union
FDAU.S. Food and Drug Administration
FitchFitch Ratings, Inc.
GAAPU.S. generally accepted accounting principles
GENEROUSGENErating cost Reductions fOr U.S. Medicaid
HHSU.S. Department of Health and Human Services
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSInternal Revenue Service
July MFN LetterLetter dated July 31, 2025, by the Administration to certain pharmaceutical manufacturers, including Amgen
Later-Stage Clinical ProgramsR&D expenses incurred in or related to phase 2 and phase 3 clinical programs intended to result in registration of a new product or a new indication for an existing product primarily in the United States or the EU
MD&Amanagement’s discussion and analysis
MFNMost-Favored-Nation
MFN EOMost-Favored-Nation Prescription Drug Pricing Executive Order
Moody’sMoody’s Investors Service, Inc.
NIHNational Institutes of Health
OB3P.L. 119-21, commonly known as The One Big Beautiful Bill Act signed into law on July 4, 2025
OECDOrganisation for Economic Co-operation and Development
PBMpharmacy benefit manager
PDABPrescription Drug Affordability Board
R&Dresearch and development
RANKLreceptor activator of nuclear factor kappa-B ligand
RARRevenue Agent Report
Research and Early PipelineR&D expenses incurred in activities substantially in support of early research through the completion of phase 1 clinical trials, including drug discovery, toxicology, pharmacokinetics and drug metabolism and process development
ROWrest of world
S&PStandard & Poor’s Financial Services LLC
SECU.S. Securities and Exchange Commission
SG&Aselling, general and administrative
SOFRSecured Overnight Financing Rate
U.S. TreasuryU.S. Department of the Treasury

ii

TermDescription
UTBunrecognized tax benefit
VBDSvanishing bile duct syndrome

iii

Products

The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are provided below.

TermDescription
ACTIMMUNEACTIMMUNE® (interferon gamma-1b)
AimovigAimovig® (erenumab-aooe)
AMJEVITA/AMGEVITAAMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab)
AranespAranesp® (darbepoetin alfa)
AVSOLAAVSOLA® (infliximab-axxq)
BKEMV/BEKEMVBKEMV® (eculizumab-aeeb)/BEKEMV™ (eculizumab)
BLINCYTOBLINCYTO® (blinatumomab)
BUPHENYLBUPHENYL® (sodium phenylbutyrate)
CorlanorCorlanor® (ivabradine)
ENBRELEnbrel® (etanercept)
EPOGENEPOGEN® (epoetin alfa)
EVENITYEVENITY® (romosozumab-aqqg)
IMDELLTRA/IMDYLLTRAIMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab)
IMLYGICIMLYGIC® (talimogene laherparepvec)
KANJINTIKANJINTI® (trastuzumab-anns)
KRYSTEXXAKRYSTEXXA® (pegloticase)
KYPROLISKYPROLIS® (carfilzomib)
LUMAKRAS/LUMYKRASLUMAKRAS®/LUMYKRAS™ (sotorasib)
MariTideMaridebart cafraglutide (MariTide™)
MVASIMVASI® (bevacizumab-awwb)
NeulastaNeulasta® (pegfilgrastim)
NEUPOGENNEUPOGEN® (filgrastim)
NplateNplate® (romiplostim)
OtezlaOtezla® (apremilast)
ParsabivParsabiv® (etelcalcetide)
PAVBLUPAVBLU® (aflibercept-ayyh)
PENNSAIDPENNSAID® (diclofenac sodium topical solution) 2%
PROCYSBIPROCYSBI® (cysteamine bitartrate)
ProliaProlia® (denosumab)
QUINSAIRQUINSAIR® (levofloxacin)
RAVICTIRAVICTI® (glycerol phenylbutyrate)
RAYOSRAYOS® (prednisone)
RepathaRepatha® (evolocumab)
RIABNIRIABNI® (rituximab-arrx)
Sensipar/MimparaSensipar®/Mimpara™ (cinacalcet)
TAVNEOSTAVNEOS® (avacopan)
TEPEZZATEPEZZA® (teprotumumab-trbw)
TEZSPIRETEZSPIRE® (tezepelumab-ekko)
UPLIZNAUPLIZNA® (inebilizumab-cdon)
VectibixVectibix® (panitumumab)
WEZLANA/WEZENLAWEZLANA® (ustekinumab-auub)/WEZENLA™ (ustekinumab)
XGEVAXGEVA® (denosumab)

Products referenced in this report that are not included in the above list are the properties of their respective owners.

iv

PART I—FINANCIAL INFORMATION

Next: Item 1. FINANCIAL STATEMENTS